Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patientsFootnote^*

* Meetings: These data were preliminarily presented at the 10th International Conference on HIV Treatment and Prevention Adherence, Miami, 28–30 June 2015.

References

• Acri, T. L., Grossberg, R. M., & Gross, R. (2010). How long is the right interval for assessing antiretroviral pharmacy refill adherence? JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(5), e16–e18. doi: 10.1097/QAI.0b013e3181ed1626
   PubMed Web of Science ®Google Scholar
• Airoldi, M., Zaccarelli, M., Bisi, L., Bini, T., Antinori, A., Mussini, C., … Maggiolo, F. (2010). One-pill once-a-day HAART: A simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Preference and Adherence, 4, 115–125.
   PubMed Web of Science ®Google Scholar
• Astuti, N., & Maggiolo, F. (2014). Single-tablet regimens in HIV therapy. Infectious Diseases and Therapy, 3(1), 1–17. doi: 10.1007/s40121-014-0024-z
   PubMedGoogle Scholar
• Austin, P. C. (2011). An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behavioral Research, 46(3), 399–424. doi: 10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Brookhart, M. A., Rassen, J. A., & Schneeweiss, S. (2010). Instrumental variable methods in comparative safety and effectiveness research. Pharmacoepidemiology and Drug Safety, 19(6), 537–554. doi: 10.1002/pds.1908
   PubMed Web of Science ®Google Scholar
• Buscher, A., Hartman, C., Kallen, M. A., & Giordano, T. P. (2012). Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naïve HIV patients. International Journal of STD & AIDS, 23(5), 351–355. doi: 10.1258/ijsa.2011.011292
   PubMed Web of Science ®Google Scholar
• Comi, L., & Maggiolo, F. (2016). Abacavir + dolutegravir + lamivudine for the treatment of HIV. Expert Opinion on Pharmacotherapy, 17(15), 2097–2106. doi: 10.1080/14656566.2016.1232387
   PubMed Web of Science ®Google Scholar
• Cotte, L., Ferry, T., Pugliese, P., Valantin, M. A., Allavena, C., Cabie, A., … Parienti, J. J. (2017). Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy – Results from a large French multicenter cohort study. PLoS ONE, 12(2), e0170661. doi: 10.1371/journal.pone.0170661
   PubMed Web of Science ®Google Scholar
• Daar, E. S., Tierney, C., Fischl, M. A., Sax, P. E., Mollan, K., Budhathoki, C., … Collier, A. C. (2011). Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Annals of Internal Medicine, 154(7), 445–456. doi: 10.7326/0003-4819-154-7-201104050-00316
   PubMed Web of Science ®Google Scholar
• Engsig, F. N., Gerstoft, J., Helleberg, M., Nielsen, L. N., Kronborg, G., Mathiesen, L. R., & Obel, N. (2014). Effectiveness of antiretroviral therapy in individuals who for economic reasons were switched from a once-daily single-tablet regimen to a triple-tablet regimen. JAIDS Journal of Acquired Immune Deficiency Syndromes, 66(4), 407–413. doi:10.1097/qai.0000000000000199. Retrieved from http://journals.lww.com/jaids/Fulltext/2014/08010/Effectiveness_of_Antiretroviral_Therapy_in.9.aspx
   PubMed Web of Science ®Google Scholar
• Falagas, M. E., Zarkadoulia, E. A., Pliatsika, P. A., & Panos, G. (2008). Socioeconomic status (SES) as a determinant of adherence to treatment in HIV infected patients: A systematic review of the literature. Retrovirology, 5, 13. doi: 10.1186/1742-4690-5-13
   PubMed Web of Science ®Google Scholar
• Gardner, E. M., McLees, M. P., Steiner, J. F., del Rio, C., & Burman, W. J. (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases, 52(6), 793–800. doi:10.1093/cid/ciq243. Retrieved from http://cid.oxfordjournals.org/content/52/6/793.abstract
   PubMed Web of Science ®Google Scholar
• Giordano, T. P., Gifford, A. L., White, A. C., Almazor, M. E. S., Rabeneck, L., Hartman, C., … Morgan, R. O. (2007). Retention in care: A challenge to survival with HIV infection. Clinical Infectious Diseases, 44(11), 1493–1499. doi:10.1086/516778. Retrieved from http://cid.oxfordjournals.org/content/44/11/1493.abstract
   PubMed Web of Science ®Google Scholar
• Hosmer, D. J., Lemeshow, S., & Sturdivant, R. (2013). Applied logistic regression. New York: Wiley.
   Google Scholar
• Kakuda, T. N., Crauwels, H., Opsomer, M., Tomaka, F., van de Casteele, T., Vanveggel, S., … de Smedt, G. (2015). Darunavir/cobicistat once daily for the treatment of HIV. Expert Review of Anti-Infective Therapy, 13(6), 691–704. doi: 10.1586/14787210.2015.1033400
   PubMed Web of Science ®Google Scholar
• Kitahata, M. M., Reed, S. D., Dillingham, P. W., Van Rompaey, S. E., Young, A. A., Harrington, R. D., & Holmes, K. K. (2004). Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. International Journal of STD & AIDS, 15(12), 803–810. doi: 10.1258/0956462042563666
   PubMed Web of Science ®Google Scholar
• Lennox, J. L., Landovitz, R. J., Ribaudo, H. J., Ofotokun, I., Na, L. H., Godfrey, C., … Currier, J. S. (2014). Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: A randomized, controlled equivalence trial. Annals of Internal Medicine, 161(7), 461–471. doi: 10.7326/m14-1084
   PubMed Web of Science ®Google Scholar
• Maggiolo, F., Airoldi, M., Kleinloog, H. D., Callegaro, A., Ravasio, V., Arici, C., … Suter, F. (2007). Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clinical Trials, 8(5), 282–292. doi: 10.1310/hct0805-282
   PubMed Web of Science ®Google Scholar
• Mills, A., Crofoot, G., Jr., McDonald, C., Shalit, P., Flamm, J. A., Gathe, J., Jr., … McCallister, S. (2015). Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: A randomized phase 2 study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 69(4), 439–445. doi: 10.1097/qai.0000000000000618
   PubMed Web of Science ®Google Scholar
• Nachega, J. B., Parienti, J. J., Uthman, O. A., Gross, R., Dowdy, D. W., Sax, P. E., … Giordano, T. P. (2014). Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clinical Infectious Diseases, 58(9), 1297–1307. doi: 10.1093/cid/ciu046
   PubMed Web of Science ®Google Scholar
• Nelson, R. E., Nebeker, J. R., Hayden, C., Reimer, L., Kone, K., & LaFleur, J. (2013). Comparing adherence to two different HIV antiretroviral regimens: An instrumental variable analysis. AIDS and Behavior, 17(1), 160–167. doi: 10.1007/s10461-012-0266-2
   PubMed Web of Science ®Google Scholar
• Rosenbaum, P., & Rubin, D. (1983). The central role of the propensity score in observational studies for causal effects. Biometrika, 70, 41–55. doi: 10.1093/biomet/70.1.41
   Web of Science ®Google Scholar
• Routman, J. S., Willig, J. H., Westfall, A. O., Abroms, S. R., Varshney, M., Adusumilli, S., … Mugavero, M. J. (2010). Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care. Clinical Infectious Diseases, 50(4), 574–584. doi: 10.1086/650004
   PubMed Web of Science ®Google Scholar
• Sattler, E. L., Lee, J. S., & Perri, M., 3rd. (2013). Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: A review of the literature. Drugs & Aging, 30(6), 383-399. doi: 10.1007/s40266-013-0074-z
   PubMed Web of Science ®Google Scholar
• Scott Sutton, S., Magagnoli, J., & Hardin, J. W. (2016). Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 36(4), 385–401. doi: 10.1002/phar.1728
   Google Scholar
• Sterrantino, G., Santoro, L., Bartolozzi, D., Trotta, M., & Zaccarelli, M. (2012). Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. Patient Preference and Adherence, 6, 427–433. doi: 10.2147/ppa.s31385
   PubMed Web of Science ®Google Scholar
• Thompson, M. A., Mugavero, M. J., Amico, K. R., Cargill, V. A., Chang, L. W., Gross, R., … Nachega, J. B. (2012). Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: Evidence-based recommendations from an international association of physicians in AIDS care panel. Annals of Internal Medicine, 156(11), 817–833, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294. doi: 10.7326/0003-4819-156-11-201206050-00419
   PubMed Web of Science ®Google Scholar
• Walensky, R. P., Sax, P. E., Nakamura, Y. M., Weinstein, M. C., Pei, P. P., Freedberg, K. A., … Schackman, B. R. (2013). Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States. Annals of Internal Medicine, 158(2), 84–92. doi: 10.7326/0003-4819-158-2-201301150-00002
   PubMed Web of Science ®Google Scholar
• Wensing, A. M., van Maarseveen, N. M., & Nijhuis, M. (2010). Fifteen years of HIV protease inhibitors: Raising the barrier to resistance. Antiviral Research, 85(1), 59–74. doi: 10.1016/j.antiviral.2009.10.003
   PubMed Web of Science ®Google Scholar